WallStreetZenWallStreetZen

NASDAQ: PRLD
Prelude Therapeutics Inc Stock Ownership - Who owns Prelude Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Prelude Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jane HuangPresident CMO2025-10-043,355$1.47
$4.93kSell
Jane HuangPresident CMO2025-07-043,355$0.79
$2.66kSell
Jane HuangPresident CMO2025-04-043,355$0.68
$2.26kSell
Andrew CombsChief Chemistry Officer2025-03-25100,000$0.69
$69.30kBuy
Krishna VaddiCEO2025-03-25675,000$0.69
$467.77kBuy
Krishna VaddiCEO2025-03-2115,000$0.73
$10.97kBuy

1 of 1

PRLD insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when PRLD insiders and whales buy or sell their stock.

PRLD Shareholders

What type of owners hold Prelude Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC17.32%10,909,256$34.04MInstitution
Baker Bros Advisors LP16.07%10,123,824$31.59MInstitution
David P. Bonita15.52%9,776,491$30.50MInsider
Orbimed Advisors LLC15.52%9,776,491$30.50MInsider
Baker Bros Advisors LP14.69%9,252,951$28.87MInsider
Krishna Vaddi4.28%2,693,625$8.40MInsider
Vanguard Group Inc2.24%1,413,986$4.41MInstitution
Kynam Capital Management LP1.25%788,867$2.46MInstitution
Two Sigma Investments LP1.25%788,695$2.46MInstitution
Price T Rowe Associates Inc1.20%755,956$2.36MInstitution

1 of 3

PRLD vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
PRLD45.19%52.26%Net Buying
CGEN13.32%0.32%
SABS41.21%58.79%Net Buying
ARCT83.37%12.98%Net Buying
TNXP19.58%80.42%Net BuyingNet Buying
View Top Biotech Stocks

Prelude Therapeutics Stock Ownership FAQ

Who owns Prelude Therapeutics?

Prelude Therapeutics (NASDAQ: PRLD) is owned by 45.19% institutional shareholders, 52.26% Prelude Therapeutics insiders, and 2.55% retail investors. David P. Bonita is the largest individual Prelude Therapeutics shareholder, owning 9.78M shares representing 15.52% of the company. David P. Bonita's Prelude Therapeutics shares are currently valued at $31.19M.

If you're new to stock investing, here's how to buy Prelude Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.